Biocodex | Date: 2017-05-03
The present invention relates to a dietary supplement or pharmaceutical composition, comprising lyophylized Saccharomyces boulardii as an active ingredient and as sole probiotic, optionally in association with a pharmaceutically acceptable vehicle, wherein the composition is in a closed vial a having a first airtight compartment comprising lyophilized S. boulardii powder, and a second compartment comprising a solution, wherein the first and second compartment can be brought in airtight communication with one another to yield a suspension of S. boulardii to be administered to an individual upon opening of the vial.
News Article | May 10, 2017
BOSTON--(BUSINESS WIRE)--PAN Communications, an integrated marketing and PR agency for the B2B technology and healthcare industries, announced that two new healthcare clients have joined the firm’s growing portfolio of innovative and disruptive brands in the digital health market. The new clients join an already impressive client portfolio pushing the firm deeper into the digital health arena and broadening the scope of its content marketing and PR expertise. The agency is already widely recognized for its knowledge and experience pertaining to healthcare IT, pharma, diagnostics and digital health products and services. “This is a very exciting time in healthcare, specifically within the digital health segment of the overall market,” said Dan Martin, VP of Client Relations at PAN. “We are witnessing new and creative ideas changing the way people engage with their healthcare, innovating how providers deliver care and supporting the way health plans and providers interact with consumers—all against a shifting political backdrop.” Joining some of PAN’s existing clients in the healthcare practice, such as Maestro Health, Biocodex and Quanterix, the newest client partners include: PAN continues to strengthen its position as a go-to agency of record for healthcare brands by investing in extensive integrated marketing and PR capabilities. The firm leads the way in terms of telling clients’ stories in the context of healthcare reform, patient safety and engagement, as well as new product and technological innovation in clinical research and studies. The firm plans to tackle the industry’s digital transformation through an array of services that create bold campaigns and seamless experiences for each customer. The digital health market is expected to grow to $379 billion by 2024. Specific segments of this growth include the wearable market ($41 billion by 2020) and the patient engagement market ($34.5 billion by 2023). Given these robust valuations across various healthcare segments, brands must be prepared to capitalize on their growth potential and seize addressable market with a single-agency partner model that encompasses social media, PR, digital, and inbound marketing. PAN is uniquely positioned to design and execute integrated content campaigns that enable emerging-market companies and established brands to stand out, reach key influencer networks and increase their awareness among stakeholders in this growing digital age. “We continue to stay ahead of the disruption taking place by advancing a broader suite of integrated content marketing and PR offerings, which is helping healthcare clients achieve their business objectives in this highly competitive and ever-changing landscape,” continued Martin. “We are thrilled to welcome these top client partners to PAN’s roster, as well as a wave of talented and experienced PR practitioners who are dedicated and passionate about healthcare.” About PAN PAN Communications is an integrated marketing and PR agency servicing B2B and healthcare technology brands. With offices in Boston, San Francisco, Orlando and New York, PAN delivers insight-driven, measurable public relations programs for leading and emerging brands nationally and globally, such as SAP, MediaMath, BlueCoat, Maestro Health and Fuze. The firm provides today’s modern marketers with communications, influencer relations, social media and digital services that build brand equity and drive business results. For more information visit our website at www.pancommunications.com, follow us on Twitter (@PANcomm) or call 617.502.4300.
Passariello A.,University of Naples Federico II |
Agricole P.,Biocodex |
Malfertheiner P.,Otto Von Guericke University of Magdeburg
Current Medical Research and Opinion | Year: 2014
Probiotics may be registered as food supplements or drugs. This article summarizes differences in European regulations of probiotics registered as food supplements and drugs, as well as issues related to the quality of probiotic products. For registration as a drug, the European Medicines Agency demands extensive and detailed quality, efficacy and safety evidence; whereas compulsory analyses requested for food supplements consist only in a nutritional analysis. As a result, the quality of those probiotics registered as drugs, compared to food supplements, is in general controlled with higher standards. Despite these differences and whatever the status of the probiotic product, its efficacy and safety has to be documented in well conducted randomized controlled trials (RCTs). Furthermore, this paper reviews recent evidence on the use of probiotics for gastrointestinal diseases, evaluating all the existing information up to January 2014. In all eligible published studies in which use of probiotics for gastrointestinal diseases were investigated and reported, no language limitations were applied. Special focus is placed on RCTs (or their meta-Analyses) showing positive results, so that the findings may be applicable to everyday clinical practice. Currently, the best documented clinical areas appear to be probiotics efficacy for the treatment of acute gastroenteritis in children and for the prevention of antibiotic-Associated diarrhea both in children and in adults. In other gastrointestinal conditions, some promising observations are emerging, but no definitive conclusions can be reached at present. © 2014 2014 Informa UK Ltd.
Biocodex | Date: 2015-06-24
The present invention relates to a compound of the following formula (I):for use in the prevention or treatment of attention deficit and/or hyperactivity in an individual.
Biocodex | Date: 2015-05-27
The present invention relates to a compound of the following formula (I):for use in the prevention or treatment of obsessions and/or compulsions in an individual.
Biocodex | Date: 2014-12-17
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of attention deficit and/or hyperactivity in an individual.
Biocodex | Date: 2014-11-07
The present invention relates to a pharmaceutical composition comprising, as active substance, Saccharomyces boulardii yeast cells, for use for reducing body fat in an individual.
Biocodex | Date: 2014-11-20
Biocodex | Date: 2015-01-28
The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, to be used in the prevention or treatment of light-induced damage and/or a degeneration of the retina in a patient.
Biocodex | Date: 2010-06-30
The present invention relates to a compound of the following formula (I):for use in the prevention or treatment of autism spectrum disorders (ASD).